BNP Paribas Financial Markets
AVDL

BNP Paribas Financial Markets’s Avadel Pharmaceuticals AVDL Stock Holding History

BNP Paribas Financial Markets’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,420
Closed -$634K – 5836
2025
Q4 		$634K Sell
29,420
-427,920
-94% -$8.31M ﹤0.01% 3436
2025
Q3 		$6.98M Buy
457,340
+434,517
+1,904% +$5.65M ﹤0.01% 1775
2025
Q2 		$202K Buy
22,823
+5,372
+31% +$47.2K ﹤0.01% 3767
2025
Q1 		$137K Sell
17,451
-5,841
-25% -$48.9K ﹤0.01% 3909
2024
Q4 		$245K Buy
+23,292
New +$283K ﹤0.01% 3749
2024
Q2 		– Sell
-4,469
Closed -$75.5K – 4044
2024
Q1 		$75.5K Buy
4,469
+1,685
+61% +$25.1K ﹤0.01% 3500
2023
Q4 		$39.3K Buy
2,784
+1,625
+140% +$19.1K ﹤0.01% 3606
2023
Q3 		$11.9K Sell
1,159
-7,347
-86% -$98.4K ﹤0.01% 3610
2023
Q2 		$140K Buy
8,506
+7,989
+1,545% +$104K ﹤0.01% 3141
2023
Q1 		$4.74K Buy
517
+73
+16% +$600 ﹤0.01% 3585
2022
Q4 		$3.18K Buy
+444
New +$3.11K ﹤0.01% 3699
2022
Q3 		– Sell
-3,298
Closed -$8.05K – 4744
2022
Q2 		$8.05K Buy
+3,298
New +$13.5K ﹤0.01% 3774
2015
Q4 		– Sell
-2
Closed -$33 – 3574
2015
Q3 		$33 Buy
+2
New +$44 ﹤0.01% 3602

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

BNP Paribas Financial Markets's AVDL Position: Q1 2026 in Review

BNP Paribas Financial Markets sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 29,420 shares — an estimated $634K sold.

BNP Paribas Financial Markets first reported a position in AVDL in Q3 2015 and held it in 13 quarters. The position peaked at $6.98M in Q3 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • BNP Paribas Financial Markets reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 29,420 Avadel Pharmaceuticals shares in Q1 2026, an estimated $634K.
  • BNP Paribas Financial Markets first reported a position in Avadel Pharmaceuticals in Q3 2015 and held it in 13 quarters.
  • BNP Paribas Financial Markets's Avadel Pharmaceuticals position peaked at $6.98M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.